Skip to content

Performance of Different Resin Infiltration Materials on White Spot Lesions: Clinical and Laboratory Assessments

Performance of Different Resin Infiltration Materials on White Spot Lesions: Clinical and Laboratory Assessments

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04673097
Enrollment
7
Registered
2020-12-17
Start date
2020-12-19
Completion date
2022-11-30
Last updated
2020-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

White Spot Lesion

Brief summary

The study is a clinical controlled trial. Ethical approval will be obtained from Imam Abdulrahman bin Faisal University, Dammam. The study participants will be recruited from the dental hospital and conducted between November 2020 to November 2020. This will be a single-center, randomized, single blinded with a 1:1:1 allocation ratio for the application of Icon® resin infiltration, MI Paste Plus and both treatments

Interventions

OTHERIcon® resin infiltration

low viscosity resin that can flow through the pores in the enamel surface

s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.

Sponsors

Imam Abdulrahman Bin Faisal University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients who are willing and able to observe good oral hygiene and attend for the study visits. * Subjects with ≥1 visible and accessible early caries lesion present. * No prior white spot lesion treatment utilized except tooth brushing with fluoridated toothpaste.

Exclusion criteria

* Active carious lesions * Facial surface restorations * Deciduous teeth * Enamel alteration (fluorosis, opacity, hypocalcification, hypoplasia) * Intrinsic and extrinsic strains * Physically and mentally challenged volunteers * Patients with systemic diseases under medication * Smokers

Design outcomes

Primary

MeasureTime frameDescription
Color improvementsChange from 0 day, 1 month and 6 monthsPre-treatment and post-treatment color changing (L\*A\*B values) of digital photographs using the Commission Internationale de l'Eclairage (CIE) system
Patient self satisfactionChange from 0 day, 1 month and 6 monthsPost-treatment patient satisfaction using the patient satisfaction scale
Change in lesion statusChange from 0 day, 1 month and 6 monthsPost-treatment change in caries lesion status using ICDAS II
Cracks of enamel.Change from 0 day, 1 month and 6 monthsNumber of cracks assessed by enamel surface analysis via silicone replicas using CLSM
Microbial composition.Change from 0 day, 1 month and 6 monthsPre-treatment and post-treatment microbial composition of plaque samples. Samples will be stored at -80 °C until DNA extractions will be performed and run the 16S rRNA sequencing.
Effects on clinical parameter: sensitivity to percussionChange from 0 day, 1 month and 6 monthsPre-treatment and post-treatment effects on sensitivity to percussion by end blunted instrument.
esthetic improvementChange from 0 day, 1 month and 6 monthsEsthetic improvement through objective assessments using a visual analogue
Patient esthetic self perceptionChange from 0 day, 1 month and 6 monthsPre-treatment esthetic self perception by the subjects using questionnaire
change in lesion sizeChange from 0 day, 1 month and 6 monthsPre-treatment and post-treatment white spot lesion size
fracture of enamel.Change from 0 day, 1 month and 6 monthsNumber of fracture assessed by enamel surface analysis via silicone replicas using CLSM
Effects on clinical parameter: prolonged response to hot or cold.Change from 0 day, 1 month and 6 monthsPre-treatment and post-treatment effects on response to hot or cold by cold test

Countries

Saudi Arabia

Contacts

Primary Contactjumanah aljishi
jumanah.aljishi@gmail.com00966534282332
Backup ContactNawarah Alaseef
Nawarah.alaseef@gmail.com00966507083741

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026